HOUSTON, April 1, 2019 /PRNewswire/ -- Soliton, Inc.,
(NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today summarized
its efforts to conduct a proof of concept clinical trial for the
treatment of cellulite based on Institutional Review Board ("IRB")
approval of the study. The study was initiated after positive
results in animal studies indicated the potential for a
higher-energy version of its acoustic shockwave technology to
affect the factors contributing to the formation of cellulite.
![Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). (PRNewsfoto/Soliton, Inc.) Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). (PRNewsfoto/Soliton, Inc.)](https://mma.prnewswire.com/media/837601/Soliton_Logo.jpg)
The study treated each thigh of five patients (n=10) with a
higher-energy version of Soliton's acoustic shockwave device with
the intent to evaluate safety and efficacy in the treatment of
cellulite. The study is designed to evaluate results at both
the 12-week and 26-week timepoints from initial treatment in order
to assess both near-term and long-term effects.
----------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
----------------------------
"Our preclinical data led us to believe we could have a
significant impact on the reduction of cellulite," commented Dr.
Chris Capelli, Soliton's President
and CEO. "This is especially significant since our technology
should represent a non-invasive, pain free treatment that requires
no anesthesia and involves no bruising, discomfort or
downtime. If we are right, we believe this could be a major
breakthrough in the treatment of cellulite."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products are
investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton's
acoustic shockwave device to reduce cellulite in the proof of
concept clinical trial. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for the year ended December 31,
2018 we filed with the SEC and updated from time to time in
our other public filings with the SEC. Any forward-looking
statements contained in this release speak only as of its date.
Soliton undertakes no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:
|
Joe Dorame, Joe Diaz
& Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-initiated-clinical-trials-for-treatment-of-cellulite-in-humans-300821569.html
SOURCE Soliton, Inc.